title: Hitting the target: where do molecularly targeted therapies fit in the treatment scheduling of neuroendocrine tumours?
abstract: Neuroendocrine tumours (NETs) are a rare and heterogeneous group of tumours whose incidence is increasing and their prevalence is now greater than that of any other upper gastrointestinal tumour. Diagnosis can be challenging, and up to 25% of patients present with metastatic disease. Following the recent FDA approval of two new molecularly targeted therapies for the treatment of advanced pancreatic NETs (pNETs), the first in 25 years, we review all systemic therapies and suggest where these newer targeted therapies fit in the treatment schedule for these challenging tumours. Clinical trial data relating to the routine use of sunitinib and everolimus in low-intermediate-grade pNETs are summarised alongside newer molecularly targeted agents undergoing clinical assessment in NETs. We particularly focus on the challenge of optimal scheduling of molecularly targeted treatments around existing systemic and localised treatment such as chemotherapy or radiotargeted therapy. We also discuss application of current evidence to subgroups of patients who have not so far been directly addressed such as those with poorer performance status or patients receiving radical surgery who may benefit from adjuvant treatment.
authors.affiliation: University College London Cancer Institute, Paul O'Gorman Building, Huntley Street, London WC1E 6BT, UK.
authors.forename: Anna
authors.initials: A
authors.lastname: Karpathakis
authors.forename: Martyn
authors.initials: M
authors.lastname: Caplin
authors.forename: Christina
authors.initials: C
authors.lastname: Thirlwell
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001984:Bronchial Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D004067:Digestive System Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D058990:Molecular Targeted Therapy; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents